Table 2.
ADMA and HOMA-IR according to angiographic CAD indices
| |
Number of vessels diseased |
|
|||
|---|---|---|---|---|---|
| 1-vessel CAD ( n = 40) | 2-vessel CAD ( n = 37) | 3-vessel CAD ( n = 74) | Pfor trend | ||
| ADMA (μmol/L) |
0.49 ± 0.10 |
0.52 ± 0.11 |
0.50 ± 0.10 |
0.3 |
|
| HOMA-IR |
3.3 (2.5–5.0) |
3.5 (2.6–5.2) |
3.0 (2.0–4.6) |
0.6 |
|
| |
Sullivan extent score |
|
|||
| |
1st quartile ≤20 |
2nd quartile 21–29 |
3rd quartile 30–41 |
4th quartile >41 |
Pfor trend |
| ADMA (μmol/L) |
0.48 ± 0.09 |
0.49 ± 0.08 |
0.52 ± 0.10 |
0.54 ± 0.11 |
0.004 |
| HOMA-IR |
3.0 (2.1–4.5) |
3.1 (2.7–4.9) |
3.5 (2.7–5.4) |
3.1 (2.3–4.8) |
0.2 |
| |
Gensini score |
|
|||
| |
1st quartile <15 |
2nd quartile 15–32 |
3rd quartile 33–64 |
4th quartile >64 |
Pfor trend |
| ADMA (μmol/L) |
0.49 ± 0.10 |
0.51 ± 0.10 |
0.50 ± 0.11 |
0.52 ± 0.12 |
0.15 |
| HOMA-IR | 3.1 (2.1–4.6) | 3.3 (2.6–5.1) | 3.0 (2.2–5.2) | 3.2 (2.5–4.8) | 0.4 |
Data are shown as mean ± SD or median (interquartile range).
Abbreviations:ADMA asymmetric dimethylarginine, CAD coronary artery disease, GFR glomerular filtration rate, HOMA-IR homeostasis model assessment for insulin resistance.